Matarin Capital Management’s NeoGenomics NEO Stock Holding History

Matarin Capital Management’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-80,233	Closed	-$893K	–	303
2017 Q3	$893K	Hold	80,233	–	–	0.08%	202
2017 Q2	$719K	Hold	80,233	–	–	0.07%	200
2017 Q1	$633K	Buy	+80,233	New	+$654K	0.06%	214

Other funds holding NEO

General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Matarin Capital Management's NEO Position: Q4 2017 in Review

Matarin Capital Management sold out of NeoGenomics (NEO) in Q4 2017, closing a stake of 80,233 shares — an estimated $893K sold.

Matarin Capital Management first reported a position in NEO in Q1 2017 and held it in 3 quarters. The position peaked at $893K in Q3 2017. 132 funds tracked by Wall St. Rank hold NEO as of Q4 2017.

Matarin Capital Management reported no remaining NeoGenomics position as of Q4 2017 after selling out during the quarter.
Matarin Capital Management sold 80,233 NeoGenomics shares in Q4 2017, an estimated $893K.
Matarin Capital Management first reported a position in NeoGenomics in Q1 2017 and held it in 3 quarters.
Matarin Capital Management's NeoGenomics position peaked at $893K in Q3 2017.
132 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2017.

Based on Matarin Capital Management's 13F filing for Q4 2017, filed 8 Feb 2018.